467 related articles for article (PubMed ID: 33430659)
1. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
[TBL] [Abstract][Full Text] [Related]
5. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S
Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133
[TBL] [Abstract][Full Text] [Related]
6. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
Isgrò C; Sardanelli AM; Palese LL
Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
10. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
Vandyck K; Deval J
Curr Opin Virol; 2021 Aug; 49():36-40. PubMed ID: 34029993
[TBL] [Abstract][Full Text] [Related]
11. Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.
Nand M; Maiti P; Joshi T; Chandra S; Pande V; Kuniyal JC; Ramakrishnan MA
Sci Rep; 2020 Nov; 10(1):20397. PubMed ID: 33230180
[TBL] [Abstract][Full Text] [Related]
12. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.
Vandyck K; Abdelnabi R; Gupta K; Jochmans D; Jekle A; Deval J; Misner D; Bardiot D; Foo CS; Liu C; Ren S; Beigelman L; Blatt LM; Boland S; Vangeel L; Dejonghe S; Chaltin P; Marchand A; Serebryany V; Stoycheva A; Chanda S; Symons JA; Raboisson P; Neyts J
Biochem Biophys Res Commun; 2021 May; 555():134-139. PubMed ID: 33813272
[TBL] [Abstract][Full Text] [Related]
13. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
14. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
15. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
[TBL] [Abstract][Full Text] [Related]
17. All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity.
Morita T; Miyakawa K; Jeremiah SS; Yamaoka Y; Sada M; Kuniyoshi T; Yang J; Kimura H; Ryo A
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452533
[TBL] [Abstract][Full Text] [Related]
18. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
[TBL] [Abstract][Full Text] [Related]
20. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.
Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T
Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
